Searchable abstracts of presentations at key conferences in endocrinology

ea0032p403 | Diabetes | ECE2013

Cardiovascular risk management in the patients with type 2 diabetes mellitus

Kim Doo-Man , Kim Sin Gon , Cho Donghyouk , Kim Chong Hwa , Kim Chul-Sik , Lee Won-Young , Won Kyu Chang

Current guidelines on cardiovascular (CV) disease prevention recommend targeted management after assessment of CV risks using many of available method even if the patient is asymptomatic. This study was performed to explore how CV high-risk is differently detected between two distinct methods: non-invasive test (NIT) and risk calculation and how the awareness of CV high-risk impacts physician and patient behavior for risk management in diabetes patient.A...

ea0022p612 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

The predictors of the response to somatostatin analogue therapy in patients with acromegaly

Kim Dong-Sun , Kim Joo-Hyung , Kim Kim Sin-Gon , Baik Sei-Hyun , Yoo Soon-Jib , Sung Yeon-Ah

Somatostatin analogues (SSA) are widely used for the treatment of patients with acromegaly, and the responses are variable. We investigated the possible predictive factors of the response to SSA therapy in Korean acromegalic patients. Twenty-eight patients were retrospectively analysed, who were treated by surgery and adjunctively SSA. Somatostatin suppression tests (SST, hourly GH measurements for 3 h following 100 μg somatostatin injection) were done before SSAs were gi...

ea0049gp91 | Diabetes &amp; complications 2 | ECE2017

Dipeptidyl peptidase-4 inhibitor therapy and risk of diabetic retinopathy: a population based study

Kim Nam Hoon , Kim Hye Suk , Yoo Hye Jin , Seo Ji A , Kim Nan Hee , Choi Kyung Mook , Baik Sei Hyun , Lee Juneyoung , Noh Jung Hyun , Kim Sin Gon

Background: Given the possible association between dipeptidyl peptidase-4 (DPP-4) inhibitor and risk of diabetic retinopathy (DR), we examined whether DPP-4 inhibitors are beneficial or harmful for DR compared with other glucose-lowering agents.Methods: From a Korean population-based cohort, we identified 67,743 adults with type 2 diabetes treated with oral glucose-lowering agents between 2008 and 2013. Matching (1:1) was done for comparative groups: eve...

ea0049ep1451 | Thyroid (non-cancer) | ECE2017

Comparative analysis of clinicopathological characteristics between Korean and Italian thyroid cancer patients

An Jee Hyun , Kim Sin Gon , Kim Hoon Yub , Jung Kwang Yoon , Chae Yang Seok , Dionigi Gianlorenzo , Rausei Stefano , Tanda Maria Laura , Piantanida Eliana , Rosa Stefano La

Background: The incidence of thyroid cancer in South Korea has increased rapidly. Increase in medical surveillance and access to health care services have enhanced the detection of asymptomatic tumors. We investigated the differences of tumor characteristics between South Korean patients and Northern Italian patients subject to different healthcare systems.Methods: The demographic, histopathologic and management features of thyroid cancer operated in two...

ea0037gp.16.03 | Diabetes and obesity–Clinical obesity and cardiovascular | ECE2015

The dipeptidyl peptidase-IV inhibitor (gemigliptin) inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms

Hong Ho Cheol , Hwang Hwan-Jin , Lee Hyun Jung , Lee Min Jung , Seo Ji A , Kim Sin Gon , Kim Nan Hee , Choi Kyung Mook , Choi Dong Seop , Baik Sei Hyun , Yoo Hye Jin

Recently, dipeptidyl peptidase-IV (DPP-IV) inhibitor, a major anti-hyperglycaemic agent, has received substantial attention as a possible therapeutic target for inflammatory diseases such as atherosclerosis. However, the direct molecular mechanisms through which DPP-IV inhibitor mediates anti-inflammatory effects in vascular endothelial cells have not been clarified. The effects of the DPP-IV inhibitor, gemigliptin, were analysed in human umbilical vein endothelial cells (HUVE...